Kensey Nash
This article was originally published in The Gray Sheet
Executive Summary
Secondary offering of 3.2 mil. shares of common stock at $9.50 each includes 2.7 mil. shares offered by the company and 500,000 offered by certain selling shareholders. A portion of the proceeds will be used to continue development of the Aegis Vortex atherectomy system to open coronary bypass grafts, conduct clinical trials and complete regulatory submissions for the device (1"The Gray Sheet" Aug. 16, 1999, p. 8). Funds also will be used for debt repayment and general corporate purposes. Prudential Vector Healthcare Group was lead manager of the offering; PaineWebber and UBS Warburg were co-managers